Skip to main content
. 2022 Nov 25;22:1219. doi: 10.1186/s12885-022-10192-4

Fig. 1.

Fig. 1

French map with estimated mean annual regional incidence rates of Lyme disease (per 100 000 inhabitants) and incidence of cetuximab-induced hypersensitivity infusion reactions (CI-IRs) in each of the four French areas

CI-IRs, cetuximab-induced hypersensitivity infusion reactions; N, number of patients